The Antitumor and Anti-angiogenic Activity of Ganoderma lucidum Polysaccharides

摘要

Ganoderma lucidum has been widely used as a medicine to promote health and longevity in China for thousands of years. A series of experiments have demonstrated that the antitumor activity of Ganoderma lucidum polysaccharides (Gl-PS) may be mediated to some extent by activation of host immune functions. In this study, we investigate the anti-angiogenic activity of Ganoderma lucidum polysaccharide (Gl-PS) on tumor growth, which maybe a new pathway of antitumor effect by Gl-PS. In present study, we investigated the antitumor activity of Gl-PS. BALB/c mice which implanted with Sarcoma 180 were administrated intragastrically with Gl-PS 50, 100, 200mg·kg<'-1> respectively for 10 days. At the end of experiment, the tumor were cut and weighted. The effect of Gl-PS and Gl-PS-treated serum on proliferation of human lung carcinoma cell line PG were detected by MTT assay; BALB/c nude mice were implanted with xenograft (human lung carcinoma cell line PG). Gl-PS were given at the dose of 50, 100, 200mg·kg<'-1> intragastrically for 32 days, then the tumor were cut and weighted. At the same time, spleen lymphocytes of the nude mice were also prepared to observe the effect of GL-PS on lymphocytes proliferation induced by 2.5μg·ml<'-1> ConA or 5μg·ml<'-1> LPS. The influence of Gl-PS on neutral red phagocytosis of nude mice peritoneal macrophages were also investigated in vitro. Gl-PS 40, 80μg·ml<'- 1> and Gl-PS-treated serum 10μl were added to the CAM (chick embryo chorioallantoic membrane) respectively to investigate the anti-angiogenesis effect of Gl-PS. The result showed that Gl-PS inhibited the growth of Sarcoma 180 significantly which had been implanted in BALB/c mice in vivo. Gl-PS inhibited the growth of Sarcoma 180 in a dose-dependent manner. The inhibitory rates were 35.20%, 45.25%, 61.88%, respectively. Gl-PS directly adding to the cultured medium did not inhibit PG cell proliferation in vitro, but 50, 100, 200mg·kg<'-1> Gl- PS-treated serum significantly inhibited PG cell proliferation, the inhibitory ratios were 22.54%, 26.76%, 30.28%. In a further study, Gl-PS 50, 100, 200mg·kg<'-1> can also inhibit the xenograft (human lung carcinoma cell line PG) in BALB/c nude mice significantly in vivo and the inhibitory rates were 55.47%, 46.04%, 46.79%, respectively. At the same time, lymphocyte proliferation experiment indicated that nude mice lymphocytes could be stimulated by LPS but not by ConA. The results above demonstrated that the cell mediated immunity was default, but Gl- PS still has high anti-tumor activity, which indicating that GL might be have other anti-tumor paths besides cell mediated immunity. The CAM assay showed that Gl-PS treated serum had anti- angiogenesis effect. In conclusion, the anti-angiogenesis of tumor may be a new mechanism of Gl-PS on tumor inhibition.